Nasdaq:US$13.74 (-0.46) | HKEX:HK$22.10 (-1.00) | AIM:£2.34 (+0)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.